Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
OSI Pharmaceuticals and Genentech have announced that the U.S. Food and Drug Administration (FDA) has approved, after priority review, Tarceva (erlotinib) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
Treating patients with advanced non-small cell lung cancer more aggressively by giving them higher doses of radiation helps keep the disease from spreading and allows some patients to live longer
Radiation therapy before chemotherapy and surgery is just as effective in treating advanced non-small cell lung cancer as chemotherapy followed by surgery then radiation
Biomira and Merck KGaA have announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track status to the investigation of BLP25 Liposome Vaccine (L-BLP25) for its proposed use in the treatment of non-small cell lung cancer (NSCLC).
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.
OSI Pharmaceuticals and Genentech have announced that OSI completed the submission of a New Drug Application with the U.S. Food and Drug Administration for Tarceva (erlotinib HCl),
Eli Lilly and Company have announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration positively endorsed Alimta® (pemetrexed), an antifolate, for accelerated approval in the second-line treatment of non-small cell lung cancer.
CancerVax Corporation has announced that its wholly owned subsidiaries, Tarcanta, Inc., and Tarcanta, Ltd. (Ireland), have obtained the exclusive rights to complete the clinical development of three specific active immunotherapeutic (SAI) product candidates that target the epidermal growth factor receptor (EGFR) signaling pathway for the treatment of cancer.
In a series of studies in breast cancer patients, researchers at The University of Texas M. D. Anderson Cancer Center have confirmed the presence of “chemobrain” after chemotherapy treatment – but they also discovered that a significant portion of patients have cognitive declines even before chemotherapy.
A chemotherapy regimen commonly used to treat non-small cell lung cancer is both more effective and more toxic in Japanese patients than in American patients, researchers reported Saturday at the annual meeting of the American Society of Clinical Oncologists.
Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).
Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.
Genetic variations in an individual’s ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows.
Progen Industries Limited, an Australian anti-cancer drug development company, announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for their lead anti-angiogenesis product PI-88 for treatment of malignant melanoma.
The combination of real-time PET and CT is a highly sensitive tool for identifying non-small cell lung cancer (NSCLC) and can assist in identifying patients whose cancer has not yet spread to lymph nodes, according to results of a study by researchers at Johns Hopkins.
Mutation of a gene involved in non-small cell lung cancer (NSCLC) increases the likelihood that the drug gefitinib (Iressa™) will show a beneficial response, researchers at the Dana-Farber Cancer Institute, the National Cancer Institute (NCI) - part of the National Institutes of Health - and two other institutions announced today in the online version of Science.
OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.
Physicians targeting lung tumors for radiation therapy can substantially improve their aim by combining data from two scanning techniques, according to Washington University researchers at Siteman Cancer Center and Barnes-Jewish Hospital in St. Louis.